Table 3.
Baseline patient characteristics
| Characteristic | Patients with CRS (n = 261) | Patients without CRS (n = 90) | P value |
|---|---|---|---|
| Median age (range, y) | 61 (18-88) | 65 (37-85) | .005 |
| Gender | .895 | ||
| Male, n (%) | 172 (66) | 60 (66.7) | |
| Female, n (%) | 89 (34.1) | 30 (33.3) | |
| Stage | .893 | ||
| I-II, n (%) | 51 (19.5) | 17 (18.9) | |
| III-IV, n (%) | 210 (80.5) | 73 (81.1) | |
| IPI score | .226 | ||
| 1-2, n (%) | 110 (46.6) | 42 (54.5) | |
| ≥3, n (%) | 126 (53.4) | 35 (45.5) | |
| Product | <.001 | ||
| Axi-cel, n (%) | 182 (69.7) | 20 (22.2) | |
| Tisa-cel, n (%) | 79 (30.3) | 70 (77.8) | |
| Disease status | |||
| Primary refractory, n (%) | 92 (37.6) | 17 (21.8) | .014 |
| Refractory, n (%) | 83 (33.9) | 27 (34.6) | |
| Relapsed, n (%) | 70 (28.6) | 34 (43.6) | |
| Bulky disease | .330 | ||
| Yes, n (%) | 44 (18.4) | 10 (13.5) | |
| No, n (%) | 195 (81.6) | 64 (86.5) | |
| Peak ferritin >5000 | <.001 | ||
| Yes, n (%) | 43 (17.8) | 1 (1.3) | |
| No, n (%) | 199 (82.2) | 75 (98.7) | |
| LDH>ULN | <.001 | ||
| Yes, n (%) | 132 (62) | 24 (36.9) | |
| No, n (%) | 81 (32) | 41 (63.1) | |
| Received steroids | <.001 | ||
| Yes, n (%) | 116 (46.2) | 4 (4.8) | |
| No, n (%) | 135 (53.8) | 79 (95.1) | |
| Received tocilizumab | <.001 | ||
| Yes, n (%) | 156 (59.5) | 11 (12.4) | |
| No, n (%) | 106 (40.5) | 78 (87.6) | |
| Use of bridging therapy | .227 | ||
| Yes, n (%) | 168 (65.3) | 63 (72.4) | |
| No, n (%) | 89 (34.6) | 24 (27.6) |